Karen L. Smith - Feb 1, 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Chief Medical Officer
Signature
/s/ Ted Monohon, Attorney-in-Fact for Karen L. Smith
Stock symbol
QNCX
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 05:35 PM
Previous filing
Jun 13, 2022
Next filing
Jun 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Employee Stock Option (right to buy) Award $0 +225K $0.00 225K Feb 1, 2023 Common Stock 225K $0.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.